374 related articles for article (PubMed ID: 26025500)
1. Testosterone Therapy after Radiation Therapy for Low, Intermediate and High Risk Prostate Cancer.
Pastuszak AW; Khanna A; Badhiwala N; Morgentaler A; Hult M; Conners WP; Sarosdy MF; Yang C; Carrion R; Lipshultz LI; Khera M
J Urol; 2015 Nov; 194(5):1271-6. PubMed ID: 26025500
[TBL] [Abstract][Full Text] [Related]
2. Testosterone replacement therapy in the setting of prostate cancer treated with radiation.
Pastuszak AW; Pearlman AM; Godoy G; Miles BJ; Lipshultz LI; Khera M
Int J Impot Res; 2013 Jan; 25(1):24-8. PubMed ID: 22971614
[TBL] [Abstract][Full Text] [Related]
3. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory.
Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
J Urol; 2011 Sep; 186(3):1005-11. PubMed ID: 21788049
[TBL] [Abstract][Full Text] [Related]
4. Testosterone Therapy in Patients with Treated and Untreated Prostate Cancer: Impact on Oncologic Outcomes.
Ory J; Flannigan R; Lundeen C; Huang JG; Pommerville P; Goldenberg SL
J Urol; 2016 Oct; 196(4):1082-9. PubMed ID: 27131465
[TBL] [Abstract][Full Text] [Related]
5. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy.
Pastuszak AW; Pearlman AM; Lai WS; Godoy G; Sathyamoorthy K; Liu JS; Miles BJ; Lipshultz LI; Khera M
J Urol; 2013 Aug; 190(2):639-44. PubMed ID: 23395803
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of Prostate Biopsy in Men with Hypogonadism Prior or During Testosterone Replacement Therapy.
Shoskes DA; Barazani Y; Fareed K; Sabanegh E
Int Braz J Urol; 2015; 41(6):1167-71. PubMed ID: 26742976
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
Morgentaler A; Rhoden EL
Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
[TBL] [Abstract][Full Text] [Related]
8. Low Serum Testosterone But Not Obesity Predicts High Gleason Score at Biopsy Diagnosed as Prostate Cancer in Patients with Serum PSA Lower than 20 ng/ml.
Shiota M; Takeuchi A; Sugimoto M; Dejima T; Kashiwagi E; Kiyoshima K; Inokuchi J; Tatsugami K; Yokomizo A
Anticancer Res; 2015 Nov; 35(11):6137-45. PubMed ID: 26504040
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
10. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.
D'Amico AV; Hui-Chen M; Renshaw AA; Sussman B; Roehl KA; Catalona WJ
J Urol; 2006 Dec; 176(6 Pt 2):S11-5. PubMed ID: 17084157
[TBL] [Abstract][Full Text] [Related]
11. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
Sarosdy MF
Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement.
Gerstenbluth RE; Maniam PN; Corty EW; Seftel AD
J Androl; 2002; 23(6):922-6. PubMed ID: 12399540
[TBL] [Abstract][Full Text] [Related]
13. Testosterone supplementation does not worsen lower urinary tract symptoms.
Pearl JA; Berhanu D; François N; Masson P; Zargaroff S; Cashy J; McVary KT
J Urol; 2013 Nov; 190(5):1828-33. PubMed ID: 23764078
[TBL] [Abstract][Full Text] [Related]
14. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
Pathak AS; Pacificar JS; Shapiro CE; Williams SG
J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
[TBL] [Abstract][Full Text] [Related]
15. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy.
Eggener SE; Roehl KA; Yossepowitch O; Catalona WJ
J Urol; 2006 Oct; 176(4 Pt 1):1399-403. PubMed ID: 16952643
[TBL] [Abstract][Full Text] [Related]
16. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia.
Rhoden EL; Morgentaler A
J Urol; 2003 Dec; 170(6 Pt 1):2348-51. PubMed ID: 14634413
[TBL] [Abstract][Full Text] [Related]
17. Sex hormone-binding globulin is an independent predictor of biochemical recurrence after radical prostatectomy.
Waldert M; Schatzl G; Swietek N; Rom M; Klatte T
J Urol; 2012 Sep; 188(3):792-7. PubMed ID: 22818139
[TBL] [Abstract][Full Text] [Related]
18. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
19. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
Grober ED; Lamb DJ; Khera M; Murthy L; Lipshultz LI
Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]